AsiaOne Online, NUS medicine researchers develop oral-anti-diabetic drug

SINGAPORE - NUS Yong Loo Lin School of Medicine has announced the successful completion of the phase I clinical trial of an oral anti-diabetic drug developed locally after 20 years of        research.  The drug molecule known as DAA-I acts on the angiotensin AT receptor and produces biological responses that improve the action of insulin, leading to increased uptake of glucose into insulin-sensitive cells. It also reduces the damaging chronic inflammation that accompanies diabetes and attenuates pancreatic beta cell death. 


« Back